- 询价
- MedChemExpress(MCE)
- 美国
- HY-L026P
- 2025年12月05日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Clinical Compound Library Plus
MCE 国际站：Clinical Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.MCE owns a unique collection of 2411 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.
Description & Advantages:
• A unique collection of 2411 clinical compounds for high throughput screening (HTS) and high content screening (HCS).
• Research areas include anticancer, anti-infection, anti inflammation, nervous disease, and more.
• A useful tool for drug repurposing.
• Currently in clinical stage, some are withdrawn or terminated.
• Structurally diverse, medicinally active, and cell permeable.
• Detailed compound information with structure, IC50, and brief introduction.
• Validated NMR and HPLC to ensure high purity and quality.
• All compounds are in stock and continuously updated.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
